Newshot
Account

Li Xiaolong on Huawei's first continuous glucose monitor, the 维感 G1: its longest-development-cycle product, first worn 35 months ago

Source: IT之家 Published: Product & Design 中文 产品
AI summary

On November 13, Huawei officially announced its first continuous glucose monitor, named the 维感 G1; Huawei Terminal BG CTO Li Xiaolong said it is the product with the longest development cycle he has worked on and the one he has beta-tested longest, noting he first wore it in December 2023, 35 months ago, and that team members started wearing it even earlier. China's NMPA published approval information on October 30 for Huawei Terminal's continuous glucose monitoring system, registration No. 国械注准 20263072228 — a Class III device, the highest level in China's regulatory system alongside cardiac stents and artificial joints — marking Huawei's entry from health monitoring into clinical-grade continuous monitoring. The 维感 G1 supports CGM, is worn on the skin, connects to Huawei smartphones and smartwatches to view details, and supports abnormal glucose alerts.

Translation(model translation, not the source's own text)

李小龙 on Huawei's first continuous glucose monitor "维感 G1": the product with the longest development cycle, 35 months since first wear

IT之家, November 13 — Today, Huawei's first continuous glucose monitor was officially announced under the name 维感 G1, and Huawei Terminal BG CTO 李小龙 reposted the related content.

He said: "This is the product with the longest development cycle for us, and also the product I have been involved in beta testing for the longest time. I remember my first wear was in December 2023, and it has been 35 months until now. The colleagues on our development team wore it much earlier than I did."

IT之家 noted that in the medical device approval document delivery information published by the National Medical Products Administration on October 30 this year, the continuous glucose monitoring system of Huawei Device Co., Ltd. appeared, with registration certificate number 国械注准 20263072228.

Class III medical devices are the highest level in China's regulatory system, on par with cardiac stents and artificial joints. Previously, Huawei's compliance path in the health monitoring field was mainly focused on Class II certificates, including the wrist dynamic blood pressure recorder, sleep apnea screening software, and pulse wave atrial fibrillation and premature beat alert software. The approval of this CGM means Huawei has moved from health monitoring into the admission range of clinical-grade continuous monitoring.

It is reported that Huawei 维感 G1 supports a continuous glucose monitoring system (CGM) and promises to provide users with an intelligent blood glucose management experience through professional capabilities. As can be seen from the official poster, Huawei 维感 G1 needs to be attached to the skin surface, and details can be viewed by connecting to a Huawei smartphone and smartwatch; it also supports features such as abnormal blood glucose alerts.

Related articles

  • 余承东 and 张兴海 shouted slogans on the same stage: AITO, built by Huawei and Seres, enters a new stage of cooperation — together, for users
  • Huawei's 余承东: 1.5 billion yuan invested in R&D for the new AITO M8, with 126 technological innovations
  • Huawei Mate X8 real device exposed: equipped with an 8-inch new BOE screen + ultra-flat crease technology
  • 启境 GT7 gets its largest OTA since launch: Huawei Qiankun ADS 5.0.2 goes live, adding gesture-based pull-out, campus navigation and more
  • 启境 GT7 Ultra Comfort Edition launched: Huawei Qiankun intelligent driving + HarmonyOS cockpit, range-extender 221,900 yuan, pure electric 231,900 yuan
  • Huawei's first continuous glucose monitor: 维感 G1 continuous glucose monitoring system announced, usable with phones and watches

The translation is machine-generated and individual terms may be off. Nothing is rewritten or cut; the original is authoritative.

Published by IT之家
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.
Read the original ↗